{"protocolSection": {"identificationModule": {"nctId": "NCT01237223", "orgStudyIdInfo": {"id": "CSPA100A1301"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension", "officialTitle": "An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2012-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-10"}, "primaryCompletionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-29", "studyFirstSubmitQcDate": "2010-11-05", "studyFirstPostDateStruct": {"date": "2010-11-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-05-11", "resultsFirstSubmitQcDate": "2012-05-11", "resultsFirstPostDateStruct": {"date": "2012-06-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-05-11", "lastUpdatePostDateStruct": {"date": "2012-06-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study was to evaluate the efficacy (blood pressure lowering effect) and safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in patients with essential hypertension (mean sitting diastolic blood pressure \\[msDBP\\] \u2265 95 mmHg and \\< 110 mmHg and mean sitting systolic blood pressure \\[msSBP\\] \u2265 140 mmHg ). This study was conducted to support registration of the fixed-dose combination of aliskiren and amlodipine for the treatment of hypertension in Japan."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["Aliskiren", "Amlodipine", "Essential hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "FACTORIAL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1342, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.", "interventionNames": ["Drug: Placebo of Aliskiren", "Drug: Placebo of Amlodipine", "Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg", "Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]}, {"label": "Aliskiren 150 mg", "type": "ACTIVE_COMPARATOR", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.", "interventionNames": ["Drug: Aliskiren 150 mg", "Drug: Placebo of Amlodipine", "Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg", "Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]}, {"label": "Amlodipine 2.5 mg", "type": "ACTIVE_COMPARATOR", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.", "interventionNames": ["Drug: Amlodipine 2.5 mg", "Drug: Placebo of Aliskiren", "Drug: Placebo of Amlodipine", "Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg", "Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]}, {"label": "Amlodipine 5 mg", "type": "ACTIVE_COMPARATOR", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.", "interventionNames": ["Drug: Amlodipine 2.5 mg", "Drug: Placebo of Aliskiren", "Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg", "Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]}, {"label": "Aliskiren/amlodipine 150/2.5 mg", "type": "EXPERIMENTAL", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period.", "interventionNames": ["Drug: Aliskiren/Amlodipine 150/2.5 mg", "Drug: Placebo of Aliskiren", "Drug: Placebo of Amlodipine", "Drug: Placebo of Aliskiren/amlodipine 150/5 mg"]}, {"label": "Aliskiren/amlodipine 150/5 mg", "type": "EXPERIMENTAL", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.", "interventionNames": ["Drug: Aliskiren/amlodipine 150/5 mg", "Drug: Placebo of Aliskiren", "Drug: Placebo of Amlodipine", "Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren/Amlodipine 150/2.5 mg", "description": "Aliskiren/amlodipine 150/2.5 mg tablet", "armGroupLabels": ["Aliskiren/amlodipine 150/2.5 mg"]}, {"type": "DRUG", "name": "Aliskiren/amlodipine 150/5 mg", "description": "Aliskiren/amlodipine 150/5 mg tablet", "armGroupLabels": ["Aliskiren/amlodipine 150/5 mg"]}, {"type": "DRUG", "name": "Aliskiren 150 mg", "description": "Aliskiren 150 mg tablet", "armGroupLabels": ["Aliskiren 150 mg"]}, {"type": "DRUG", "name": "Amlodipine 2.5 mg", "description": "Amlodipine 2.5 mg capsule", "armGroupLabels": ["Amlodipine 2.5 mg", "Amlodipine 5 mg"]}, {"type": "DRUG", "name": "Placebo of Aliskiren", "description": "Aliskiren placebo tablet", "armGroupLabels": ["Aliskiren/amlodipine 150/2.5 mg", "Aliskiren/amlodipine 150/5 mg", "Amlodipine 2.5 mg", "Amlodipine 5 mg", "Placebo"]}, {"type": "DRUG", "name": "Placebo of Amlodipine", "description": "Amlodipine placebo capsule", "armGroupLabels": ["Aliskiren 150 mg", "Aliskiren/amlodipine 150/2.5 mg", "Aliskiren/amlodipine 150/5 mg", "Amlodipine 2.5 mg", "Placebo"]}, {"type": "DRUG", "name": "Placebo of Aliskiren/amlodipine 150/2.5 mg", "description": "Aliskiren/amlodipine 150/2.5 mg placebo tablet", "armGroupLabels": ["Aliskiren 150 mg", "Aliskiren/amlodipine 150/5 mg", "Amlodipine 2.5 mg", "Amlodipine 5 mg", "Placebo"]}, {"type": "DRUG", "name": "Placebo of Aliskiren/amlodipine 150/5 mg", "description": "Aliskiren/amlodipine 150/5 mg placebo tablet", "armGroupLabels": ["Aliskiren 150 mg", "Aliskiren/amlodipine 150/2.5 mg", "Amlodipine 2.5 mg", "Amlodipine 5 mg", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)", "description": "Sitting blood pressure was measured at trough (24 hours \u00b1 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.", "timeFrame": "Baseline, Week 8"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)", "description": "Sitting blood pressure was measured at trough (24 hours \u00b1 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.", "timeFrame": "Baseline, Week 8"}, {"measure": "Percentage of Participants Achieving Blood Pressure Control at Endpoint", "description": "Blood pressure control is defined as having as a msDBP \\< 90 mmHg and a msSBP \\< 140 mmHg.", "timeFrame": "8 weeks"}, {"measure": "Percentage of Participants Achieving a Successful Response Rate", "description": "The response rate was defined as percentage of participants who achieved msDBP \\< 90 mmHg or its reduction \u2265 10 mmHg from baseline to endpoint.", "timeFrame": "8 weeks"}, {"measure": "Number of Participants With Adverse Events, Serious Adverse Events and Death", "description": "Number of patients with adverse events regardless of study drug relationship during the double-blind treatment period were reported. Serious adverse events of double blind period were reported.", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with essential hypertension (msDBP \u2265 95 mmHg and \\< 110 mmHg and msSBP \u2265140 mmHg )\n* Outpatients\n\nExclusion Criteria:\n\n* Severe hypertension (msDBP \u2265110 mmHg and/or msSBP \u2265 180 mmHg)\n* History of allergy or hypersensitivity to renin inhibitors, calcium channel blockers\n* History or evidence of a secondary hypertension\n\nOther protocol-defined inclusion/exclusion criteria applied", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigative Site", "city": "Aichi", "country": "Japan", "geoPoint": {"lat": 32.51879, "lon": 130.62158}}, {"facility": "Investigative Site", "city": "Ehime", "country": "Japan", "geoPoint": {"lat": 33.63163, "lon": 132.76886}}, {"facility": "Investigative Site", "city": "Fukuoka", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Investigative Site", "city": "Hokkaido", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "Investigative Site", "city": "Hyogo", "country": "Japan"}, {"facility": "Investigative Site", "city": "Kanagawa", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "Investigative Site", "city": "Kyoto", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Investigative Site", "city": "Okayama", "country": "Japan", "geoPoint": {"lat": 34.65, "lon": 133.93333}}, {"facility": "Investigative Site", "city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Investigative Site", "city": "Saitama", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "Investigative Site", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily."}, {"id": "FG001", "title": "Aliskiren 150 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "FG002", "title": "Amlodipine 2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "FG003", "title": "Amlodipine 5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "FG004", "title": "Aliskiren/Amlodipine 150/2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "FG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}], "periods": [{"title": "Single Blind(Run-in Period, 4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "All the patients enrolled to single blind period received only placebo treatment.", "numSubjects": "1342"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "944"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "398"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "308"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "28"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Protocol deviation(s)", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Double Blind (Treatment Period, 8 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "153"}, {"groupId": "FG001", "numSubjects": "157"}, {"groupId": "FG002", "numSubjects": "158"}, {"groupId": "FG003", "numSubjects": "158"}, {"groupId": "FG004", "numSubjects": "159"}, {"groupId": "FG005", "numSubjects": "159"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "120"}, {"groupId": "FG001", "numSubjects": "142"}, {"groupId": "FG002", "numSubjects": "143"}, {"groupId": "FG003", "numSubjects": "153"}, {"groupId": "FG004", "numSubjects": "155"}, {"groupId": "FG005", "numSubjects": "154"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Protocol deviation(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily for 8 weeks of double blind period."}, {"id": "BG001", "title": "Aliskiren 150 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "BG002", "title": "Amlodipine 2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "BG003", "title": "Amlodipine 5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "BG004", "title": "Aliskiren/Amlodipine 150/2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "BG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "153"}, {"groupId": "BG001", "value": "157"}, {"groupId": "BG002", "value": "158"}, {"groupId": "BG003", "value": "158"}, {"groupId": "BG004", "value": "159"}, {"groupId": "BG005", "value": "159"}, {"groupId": "BG006", "value": "944"}]}], "measures": [{"title": "Age Continuous", "description": "Baseline measurements were based on randomized patients.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.6", "spread": "8.35"}, {"groupId": "BG001", "value": "55.0", "spread": "9.96"}, {"groupId": "BG002", "value": "54.8", "spread": "10.25"}, {"groupId": "BG003", "value": "55.8", "spread": "10.05"}, {"groupId": "BG004", "value": "54.6", "spread": "11.11"}, {"groupId": "BG005", "value": "55.5", "spread": "9.86"}, {"groupId": "BG006", "value": "55.1", "spread": "9.96"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "131"}, {"groupId": "BG002", "value": "129"}, {"groupId": "BG003", "value": "126"}, {"groupId": "BG004", "value": "125"}, {"groupId": "BG005", "value": "127"}, {"groupId": "BG006", "value": "766"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "29"}, {"groupId": "BG003", "value": "32"}, {"groupId": "BG004", "value": "34"}, {"groupId": "BG005", "value": "32"}, {"groupId": "BG006", "value": "178"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "45"}, {"groupId": "BG003", "value": "51"}, {"groupId": "BG004", "value": "51"}, {"groupId": "BG005", "value": "57"}, {"groupId": "BG006", "value": "288"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "118"}, {"groupId": "BG002", "value": "113"}, {"groupId": "BG003", "value": "107"}, {"groupId": "BG004", "value": "108"}, {"groupId": "BG005", "value": "102"}, {"groupId": "BG006", "value": "656"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8)", "description": "Sitting blood pressure was measured at trough (24 hours \u00b1 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.", "populationDescription": "Full analysis set (FAS): All randomized patients received at least one dose of double-blind study medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily for 8 weeks of double blind treatment period."}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG002", "title": "Amlodipine 2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG003", "title": "Amlodipine 5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG004", "title": "Aliskiren/Amlodipine 150/2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "157"}, {"groupId": "OG002", "value": "158"}, {"groupId": "OG003", "value": "158"}, {"groupId": "OG004", "value": "159"}, {"groupId": "OG005", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.21", "spread": "0.69"}, {"groupId": "OG001", "value": "-7.49", "spread": "0.68"}, {"groupId": "OG002", "value": "-9.46", "spread": "0.68"}, {"groupId": "OG003", "value": "-11.90", "spread": "0.68"}, {"groupId": "OG004", "value": "-12.40", "spread": "0.68"}, {"groupId": "OG005", "value": "-16.43", "spread": "0.68"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8)", "description": "Sitting blood pressure was measured at trough (24 hours \u00b1 2 hours post dose) and recorded at all study visits. At the first study visit, blood pressure was measured in both arms and the arm with highest sitting DBP was found and used for all subsequent readings throughout the study. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these three sitting blood pressure measurements were used as the average sitting blood pressure for that visit. Analysis of covariance (ANCOVA) model contained treatment and region as two factors and baseline as a covariate.", "populationDescription": "Full analysis set (FAS): All randomized patients received at least one dose of double-blind study medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily for 8 weeks of double blind period."}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG002", "title": "Amlodipine 2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG003", "title": "Amlodipine 5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG004", "title": "Aliskiren/Amlodipine 150/2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "157"}, {"groupId": "OG002", "value": "158"}, {"groupId": "OG003", "value": "158"}, {"groupId": "OG004", "value": "159"}, {"groupId": "OG005", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.57", "spread": "0.97"}, {"groupId": "OG001", "value": "-10.63", "spread": "0.96"}, {"groupId": "OG002", "value": "-13.16", "spread": "0.96"}, {"groupId": "OG003", "value": "-17.98", "spread": "0.96"}, {"groupId": "OG004", "value": "-18.15", "spread": "0.96"}, {"groupId": "OG005", "value": "-25.49", "spread": "0.96"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Blood Pressure Control at Endpoint", "description": "Blood pressure control is defined as having as a msDBP \\< 90 mmHg and a msSBP \\< 140 mmHg.", "populationDescription": "Full analysis set (FAS) included all randomized patients received at least one dose of double-blind study medication", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily for 8 weeks of double blind period."}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG002", "title": "Amlodipine 2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG003", "title": "Amlodipine 5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG004", "title": "Aliskiren/Amlodipine 150/2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "157"}, {"groupId": "OG002", "value": "158"}, {"groupId": "OG003", "value": "158"}, {"groupId": "OG004", "value": "159"}, {"groupId": "OG005", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.3"}, {"groupId": "OG001", "value": "25.5"}, {"groupId": "OG002", "value": "32.9"}, {"groupId": "OG003", "value": "50.0"}, {"groupId": "OG004", "value": "45.9"}, {"groupId": "OG005", "value": "69.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Successful Response Rate", "description": "The response rate was defined as percentage of participants who achieved msDBP \\< 90 mmHg or its reduction \u2265 10 mmHg from baseline to endpoint.", "populationDescription": "Full analysis set (FAS) included all randomized patients received at least one dose of double-blind study medication", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily for 8 weeks of double blind period."}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG002", "title": "Amlodipine 2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG003", "title": "Amlodipine 5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG004", "title": "Aliskiren/Amlodipine 150/2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "157"}, {"groupId": "OG002", "value": "158"}, {"groupId": "OG003", "value": "158"}, {"groupId": "OG004", "value": "159"}, {"groupId": "OG005", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34.6"}, {"groupId": "OG001", "value": "46.5"}, {"groupId": "OG002", "value": "50.6"}, {"groupId": "OG003", "value": "70.3"}, {"groupId": "OG004", "value": "65.4"}, {"groupId": "OG005", "value": "86.2"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events, Serious Adverse Events and Death", "description": "Number of patients with adverse events regardless of study drug relationship during the double-blind treatment period were reported. Serious adverse events of double blind period were reported.", "populationDescription": "Safety set: All patients who received at least one dose of double-blind study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily for 8 weeks of double blind period."}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG002", "title": "Amlodipine 2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."}, {"id": "OG003", "title": "Amlodipine 5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG004", "title": "Aliskiren/Amlodipine 150/2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."}, {"id": "OG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "157"}, {"groupId": "OG002", "value": "158"}, {"groupId": "OG003", "value": "158"}, {"groupId": "OG004", "value": "159"}, {"groupId": "OG005", "value": "159"}]}], "classes": [{"title": "Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "50"}, {"groupId": "OG003", "value": "49"}, {"groupId": "OG004", "value": "57"}, {"groupId": "OG005", "value": "59"}]}]}, {"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "1"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Placebo (Double Blind)", "description": "In order to adequately blind the study,patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.", "seriousNumAffected": 0, "seriousNumAtRisk": 153, "otherNumAffected": 21, "otherNumAtRisk": 153}, {"id": "EG001", "title": "Aliskiren 150 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.", "seriousNumAffected": 0, "seriousNumAtRisk": 157, "otherNumAffected": 21, "otherNumAtRisk": 157}, {"id": "EG002", "title": "Amlodipine 2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.", "seriousNumAffected": 2, "seriousNumAtRisk": 158, "otherNumAffected": 17, "otherNumAtRisk": 158}, {"id": "EG003", "title": "Amlodipine 5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.", "seriousNumAffected": 1, "seriousNumAtRisk": 158, "otherNumAffected": 21, "otherNumAtRisk": 158}, {"id": "EG004", "title": "Aliskiren/Amlodipine 150/2.5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period.", "seriousNumAffected": 0, "seriousNumAtRisk": 159, "otherNumAffected": 17, "otherNumAtRisk": 159}, {"id": "EG005", "title": "Aliskiren/Amlodipine 150/5 mg", "description": "In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.\n\nPatients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.", "seriousNumAffected": 1, "seriousNumAtRisk": 159, "otherNumAffected": 19, "otherNumAtRisk": 159}, {"id": "EG006", "title": "Placebo (Single-Blind run-in Period)", "description": "In order to adequately blind the study,patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in period (4 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.", "seriousNumAffected": 4, "seriousNumAtRisk": 1342, "otherNumAffected": 136, "otherNumAtRisk": 1342}], "seriousEvents": [{"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 1342}]}, {"term": "Herpes zoster oticus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 1342}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 1342}]}, {"term": "Pelvic fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 1342}]}, {"term": "Hypertensive encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 1342}]}, {"term": "Putamen haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 1342}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 1342}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 1342}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 19, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 16, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 16, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 81, "numAtRisk": 1342}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 153}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 157}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 158}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 158}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG005", "numAffected": 3, "numAtRisk": 159}, {"groupId": "EG006", "numAffected": 59, "numAtRisk": 1342}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}